

FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009
EXP CS-682/CN
EXP CS682/CN
EXP CS 682/CN
L1 1 S E3
EXP 1-(2-C-CYANO/CN
EXP 1-(2-CYANO/CN
EXP 1-(2-CYANO-2-DEOXY/CN

FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009
L2 28 S L1
L3 32326 S CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009

FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009
L4 28 S L1 AND L2
L5 29617 S CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4
L6 4 S L2 AND L5

FILE 'REGISTRY' ENTERED AT 12:58:20 ON 02 MAY 2009
EXP CNDAC/CN
L7 1 S E3

FILE 'HCAPLUS' ENTERED AT 12:58:40 ON 02 MAY 2009
L8 51 S L7
L9 1 S L5 AND L8

FILE 'REGISTRY' ENTERED AT 13:00:41 ON 02 MAY 2009
EXP ROISOVITINE/CN
EXP ROSCOVITINE/CN
L10 1 S E3
L11 0 S PURVALANOL/CN
EXP PURVALANOL/CN
L12 2 S E4-E5
EXP OLOMOUCINE/CN
L13 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:01:55 ON 02 MAY 2009
L14 708 S L10 OR L12 OR L13
L15 3 S (L2 OR L8) AND L14

=> file regisry
'REGISRY' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 APR 2009 HIGHEST RN 1141557-64-3
DICTIONARY FILE UPDATES: 30 APR 2009 HIGHEST RN 1141557-64-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp CS-682/cn

E1	1	CS-144M/CN
E2	1	CS-516/CN
E3	0 -->	CS-682/CN
E4	1	CS-7002/CN
E5	1	CS-728/CN
E6	1	CS-80L/CN
E7	1	CS-834 DIHYDRATE/CN
E8	1	CS-834 MONOHYDRATE/CN
E9	1	CS-ACT CEREBROSIDE SULFATE ACTIVATOR GLYCOPROTEIN (PIG KIDNE Y)/CN
E10	1	CS-AU 44JO/CN
E11	1	CS-AV 44IO/CN
E12	1	CS-BK 100Y/CN

=> exp CS682/cn

E1	1	CS61+/CN
E2	1	CS6790/CN
E3	0 -->	CS682/CN
E4	1	CS6NA18SN46/CN
E5	1	CS7/CN
E6	1	CS7+/CN
E7	1	CS71+/CN

E8	1	CS74A/CN
E9	1	CS8/CN
E10	1	CS8+/CN
E11	1	CS81+/CN
E12	1	CS8GA8SN38/CN

=> exp CS 682/cn

E1	1	CS 670/CN
E2	1	CS 674A/CN
E3	1 -->	CS 682/CN
E4	1	CS 684/CN
E5	1	CS 6DE/CN
E6	1	CS 6E227/CN
E7	1	CS 6E227S/CN
E8	1	CS 6PA/CN
E9	1	CS 6PA422CB/CN
E10	1	CS 6PA473/CN
E11	1	CS 6PE231/CN
E12	1	CS 6PE401/CN

=> s e3

L1 1 "CS 682"/CN


=> d l1

<-----User Break----->

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 151823-14-2 REGISTRY
 ED Entered STN: 17 Dec 1993
 CN Hexadecanamide, N-[1-(2-cyano-2-deoxy- β -D-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]- (CA INDEX NAME)
 OTHER NAMES:
 CN CS 682
 CN CYC 682
 CN Sapacitabine
 FS STEREOSEARCH
 MF C26 H42 N4 O5
 SR CA
 LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

27 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 28 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> exp 1-(2-C-cyano/cn

E1	1	1-(2-BUTYRYLOXYETHOXY)ETHYL METHACRYLATE/CN
E2	1	1-(2-C-ALLYL-B-D-RIBOFURANOSYL) THYMINE/CN
E3	0 -->	1-(2-C-CYANO/CN
E4	1	1-(2-CARBAMOYL-1-METHYLETHYL)-1-METHYLPYRROLIDINIUM IODIDE/CN
E5	1	1-(2-CARBAMOYL-1-METHYLETHYL)PYRIDINIUM BROMIDE/CN
E6	1	1-(2-CARBAMOYL-1-METHYLETHYL)PYRIDINIUM CHLORIDE/CN
E7	1	1-(2-CARBAMOYL-1-METHYLETHYL)PYRIDINIUM IODIDE/CN
E8	1	1-(2-CARBAMOYL-4-(6-FLUORO-7-(METHYLAMINO)-4-OXO-2H-BENZO(E)(1,3)OXAZIN-3(4H)-YL)PHENYL)-3-(5-CHLOROTHIOPHEN-2-YL)SULFONYL)UREA/CN
E9	1	1-(2-CARBAMOYLETHYL)-1-METHYLPYRROLIDINIUM BROMIDE/CN
E10	1	1-(2-CARBAMOYLETHYL)-1-PYRIDINIUM METHANESULFONATE/CN
E11	1	1-(2-CARBAMOYLETHYL)-2-(P-DIETHYLAMINOPHENYL)BENZ(CD)INDOLINUM CHLORIDE/CN
E12	1	1-(2-CARBAMOYLETHYL)-2-METHYLPYRIDINIUM PICRATE/CN

=> exp 1-(2-cyano/cn

E1	1	1-(2-CIS-(4-AZIDO-3-((TERT-BUTYLDIMETHYLSILYL)OXY)PIPERIDIN-1-YL)ETHYL)-2-OXO-1,2-DIHYDROQUINOLINE-7-CARBONITRILE/CN
E2	1	1-(2-CIS-(4-AZIDO-3-HYDROXYPIPERIDIN-1-YL)ETHYL)-2-OXO-1,2-DIHYDROQUINOLINE-7-CARBONITRILE/CN
E3	0 -->	1-(2-CYANO/CN
E4	1	1-(2-CYANO-1-METHYLETHYL)-2-ETHYLIMIDAZOLE/CN
E5	1	1-(2-CYANO-1-METHYLETHYL)-2-ETHYLIMIDAZOLE MONOPICRATE/CN
E6	1	1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE/CN
E7	1	1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE MONOPICRATE/CN
E8	1	1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID/CN
E9	1	1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER/CN
E10	1	1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-BUTYLUREA/CN
E11	1	1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-METHYLUREA/CN
E12	1	1-(2-CYANO-3-METHYLPHENOXY)-2,3-EPOXYPROPANE/CN

=> exp 1-(2-cyano-2-deoxy/cn

E1	1	1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE/CN
E2	1	1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE MONOPICRATE/CN
E3	0 -->	1-(2-CYANO-2-DEOXY/CN
E4	1	1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID/CN
E5	1	1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER/CN
E6	1	1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-BUTYLUREA/CN
E7	1	1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-METHYLUREA/CN
E8	1	1-(2-CYANO-3-METHYLPHENOXY)-2,3-EPOXYPROPANE/CN
E9	1	1-(2-CYANO-3-METHYLPHENOXY)-2-HYDROXY-3-ISOPROPYLAMINOPROPANOL HYDROCHLORIDE/CN
E10	1	1-(2-CYANO-3-METHYLPHENOXY)-2-HYDROXY-3-TERT-BUTYLAMINOPROPANOL HYDROCHLORIDE/CN
E11	1	1-(2-CYANO-3-PYRAZINYL)-4-(3-(6-METHYL-2-PYRIDYL)-2-PROPYNYLIDENE)PIPERIDINE/CN

E12 1 1-(2-CYANO-3-TRIFLUOROMETHYLPHENYL)PIPERAZINE/CN

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.70

12.92

FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2009 VOL 150 ISS 19

FILE LAST UPDATED: 1 May 2009 (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12

L2 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 11

L2 28 L1

=> s CDC or (cyclin dependent kinase) or CDC2 or CDC4

3564 CDC

40000 CYCLIN

1214183 DEPENDENT

348522 KINASE

25058 CYCLIN DEPENDENT KINASE

(CYCLIN(W)DEPENDENT(W)KINASE)

4823 CDC2

237 CDC4

L3 32326 CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.85

15.77

FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 24, 2009 (20090424/UP).

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.14	15.91

FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 1 May 2009 (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 11 and 12
      28 L1
L4      28 L1 AND L2

=> s CDk or (cyclin dependent kinase) or CDk2 or CDk4
      6363 CDK
      40000 CYCLIN
      1214183 DEPENDENT
      348522 KINASE
      25058 CYCLIN DEPENDENT KINASE
            (CYCLIN(W)DEPENDENT(W)KINASE)
      5724 CDK2
      4188 CDK4
L5      29617 CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4

=> s 12 and 15
L6      4 L2 AND L5

=> d 16 1-4 ti abs bib
```

L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions of placentally-derived stem cells for the treatment of cancer
AB Disclosed are preps. of placentally-derived stem cells and compns. useful for the treatment of cancer. Said stem cells and compns. function through inducing a "guided differentiation" program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.

AN 2007:86292 HCAPLUS <<LOGINID::20090502>>

DN 146:169222

TI Compositions of placentally-derived stem cells for the treatment of cancer

IN Ichim, Thomas E.

PA Medistem Laboratories, Inc., USA

SO PCT Int. Appl., 41pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007011693	A2	20070125	WO 2006-US27305	20060712
	WO 2007011693	A3	20070510		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20070041954	A1	20070222	US 2006-486635	20060713
PRAI	US 2005-699579P	P	20050714		

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof

AB A first aspect of the invention relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy- β -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy- β -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or sep. use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or sep. administering a CDK inhibitor and 1-(2-C-cyano-2-dioxy- β -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.

AN 2005:523291 HCAPLUS <<LOGINID::20090502>>

DN 143:48129

TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof

IN Green, Simon; Sleigh, Roger Neil

PA Cyclacel Limited, UK

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005053699	A1	20050616	WO 2004-GB5081	20041203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1711185	A1	20061018	EP 2004-805910	20041203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007513132	T	20070524	JP 2006-542014	20041203
	US 20070270442	A1	20071122	US 2007-581585	20070420
PRAI	GB 2003-28180	A	20031204		
	WO 2004-GB5081	W	20041203		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
AB The invention discloses the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
AN 2004:1036851 HCAPLUS <<LOGINID::20090502>>
DN 142:696
TI Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
IN Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin
PA Hybridon, Inc., USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103301	A2	20041202	WO 2004-US15313	20040514
	WO 2004103301	A3	20051103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004241093	A1	20041202	AU 2004-241093	20040514

CA 2526212	A1	20041202	CA 2004-2526212	20040514
US 20050009773	A1	20050113	US 2004-846167	20040514
EP 1628531	A2	20060301	EP 2004-752345	20040514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006528697	T	20061221	JP 2006-533117	20040514
MX 2005012421	A	20060222	MX 2005-12421	20051116
US 20080206265	A1	20080828	US 2008-20694	20080128
PRAI US 2003-471247P	P	20030516		
US 2004-846167	A1	20040514		
WO 2004-US15313	W	20040514		
OS MARPAT 142:696				
RE.CNT 4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L6 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Methods for enhancing antibody-induced cell lysis and treating cancer
 AB The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.
 AN 2001:935435 HCAPLUS <<LOGINID::20090502>>
 DN 136:84677
 TI Methods for enhancing antibody-induced cell lysis and treating cancer
 IN Weiner, George; Hartmann, Gunther
 PA University of Iowa Research Foundation, USA
 SO PCT Int. Appl., 312 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001097843	A2	20011227	WO 2001-US20154	20010622
	WO 2001097843	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2410371	A1	20011227	CA 2001-2410371	20010622
	AU 2001070134	A	20020102	AU 2001-70134	20010622
	US 20030026801	A1	20030206	US 2001-888326	20010622
	EP 1296714	A2	20030402	EP 2001-948684	20010622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003535907	T	20031202	JP 2002-503327	20010622
	AU 2001270134	B2	20060615	AU 2001-270134	20010622
	AU 2006216542	A1	20061012	AU 2006-216542	20060915
PRAI	US 2000-213346P	P	20000622		
	AU 2001-270134	A3	20010622		
	WO 2001-US20154	W	20010622		
RE.CNT 2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=> d his

(FILE 'HOME' ENTERED AT 12:43:26 ON 02 MAY 2009)

FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009

EXP CS-682/CN

EXP CS682/CN

EXP CS 682/CN

L1 1 S E3

EXP 1-(2-C-CYANO/CN

EXP 1-(2-CYANO/CN

EXP 1-(2-CYANO-2-DEOXY/CN

FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009

L2 28 S L1

L3 32326 S CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009

FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009

L4 28 S L1 AND L2

L5 29617 S CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4

L6 4 S L2 AND L5

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.85	30.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.28	-3.28

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:48:11 ON 02 MAY 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'HCAPLUS' AT 12:58:06 ON 02 MAY 2009

FILE 'HCAPLUS' ENTERED AT 12:58:06 ON 02 MAY 2009

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.85	30.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.28	-3.28

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FULL ESTIMATED COST	14.85	30.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.28	-3.28

FILE 'REGISTRY' ENTERED AT 12:58:20 ON 02 MAY 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 30 APR 2009 HIGHEST RN 1141557-64-3
 DICTIONARY FILE UPDATES: 30 APR 2009 HIGHEST RN 1141557-64-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp CNDAC/cn

E1	1	CNC68/CN
E2	1	CNCC/CN
E3	1 -->	CNDAC/CN
E4	1	CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (HUMAN CLON E MGC:4413 IMAGE:2957870)/CN
E5	1	CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (HUMAN CLON E MGC:928 IMAGE:3051369)/CN
E6	1	CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (MOUSE STRA IN MIX FVB/N, C57BL/6J CLONE MGC:7671 IMAGE:3496319)/CN
E7	1	CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (XENOPUS TR OPICALIS CLONE MGC:75655 IMAGE:5379710 GENE CNDP2-PROV)/CN
E8	1	CNDP2-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:82085 IMAGE:701 1654 GENE CNDP2-PROV)/CN
E9	1	CNDR-29/CN
E10	1	CNDR-3/CN
E11	1	CNE 195LB/CN
E12	1	CNE 195XL2/CN

=> s e3


L7 1 CNDAC/CN

=> d 17

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 135598-68-4 REGISTRY
 ED Entered STN: 16 Aug 1991
 CN 2(1H)-Pyrimidinone, 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-
 (CA INDEX NAME)
 OTHER NAMES:

CN CNDAC
 FS STEREOSEARCH
 MF C10 H12 N4 O4
 CI COM
 SR CA
 LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, IMSRESEARCH,
 PROUSDDR, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

51 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 51 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.88	38.64

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.28

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 12:58:40 ON 02 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2009 VOL 150 ISS 19

FILE LAST UPDATED: 1 May 2009 (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17

L8 51 L7

=> s 15 and 18

L9 1 L5 AND L8

=> d 19 ti abs bib

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1- β -D-arabino-pentofuranosylcytosine

AB 2'-C-Cyano-2'-deoxy-1- β -D-arabino-pentofuranosylcytosine (CNDAC), the prodrug (sapacitabine) of which is in clin. trials, has the novel mechanism of action of causing single-strand breaks after incorporating into DNA. Cells respond to this unique lesion by activating the G2 checkpoint, affected by the Chk1-Cdc25C-cyclin-dependent kinase 1/cyclin B pathway. This study aims at defining DNA damage checkpoint sensors that activate this response to CNDAC, particularly focusing on the major phosphatidylinositol 3-kinase-like protein kinase family proteins. First, fibroblasts, deficient in ataxia-telangiectasia mutated (ATM), transfected with empty vector or repleted with ATM, were arrested in G2 by CNDAC to similar extents, suggesting ATM is not required to activate the G2 checkpoint. Second, chromatin assocns. of RPA70 and RPA32, subunits of the ssDNA-binding protein, and the ataxia-telangiectasia and Rad3-related (ATR) substrate Rad17 and its phosphorylated form were increased on CNDAC exposure, suggesting activation of ATR kinase. The G2 checkpoint was abrogated due to depletion of ATR by small interfering RNA, and impaired in ATR-Seckel cells, indicating participation of ATR in this G2 checkpoint pathway. Third, the G2 checkpoint was more stringent in glioma cells with wild-type DNA-dependent protein kinase catalytic subunit (DNA-PKcs) than those with mutant DNA-PKcs, as shown by mitotic index counting. CNDAC-induced G2 arrest was abrogated by specific DNA-PKcs inhibitors or small interfering RNA knockdown in ML-1 and/or HeLa cells. Finally, two phosphatidylinositol 3-kinase-like protein kinase inhibitors, caffeine and wortmannin, abolished the CNDAC-induced G2 checkpoint in a spectrum of cell lines. Together, our data showed that ATR and DNA-PK cooperate in CNDAC-induced activation of the G2 checkpoint pathway. [Mol Cancer Ther 2008;7(1):133-42].

AN 2008:64824 HCAPLUS <<LOGINID::20090502>>

DN 148:322141

TI Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1- β -D-arabino-pentofuranosylcytosine

AU Liu, Xiaojun; Matsuda, Akira; Plunkett, William

CS Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

SO Molecular Cancer Therapeutics (2008), 7(1), 133-142
CODEN: MCTOCF; ISSN: 1535-7163

PB American Association for Cancer Research

DT Journal

LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:43:26 ON 02 MAY 2009)

FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009

EXP CS-682/CN

EXP CS682/CN

EXP CS 682/CN

L1 1 S E3
EXP 1-(2-C-CYANO/CN
EXP 1-(2-CYANO/CN
EXP 1-(2-CYANO-2-DEOXY/CN

FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009

L2 28 S L1

L3 32326 S CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009

FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009

L4 28 S L1 AND L2

L5 29617 S CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4

L6 4 S L2 AND L5

FILE 'REGISTRY' ENTERED AT 12:58:20 ON 02 MAY 2009

EXP CNDAC/CN

L7 1 S E3

FILE 'HCAPLUS' ENTERED AT 12:58:40 ON 02 MAY 2009

L8 51 S L7

L9 1 S L5 AND L8

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.85	44.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.82	-4.10

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:59:29 ON 02 MAY 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 13:00:33 ON 02 MAY 2009

FILE 'HCAPLUS' ENTERED AT 13:00:33 ON 02 MAY 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)f

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.85	44.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.82	-4.10

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.85	44.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.82	-4.10

FILE 'REGISTRY' ENTERED AT 13:00:41 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 APR 2009 HIGHEST RN 1141557-64-3
DICTIONARY FILE UPDATES: 30 APR 2009 HIGHEST RN 1141557-64-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp rosovitine/cn

E1	1	ROSOPHENINE 4B/CN
E2	1	ROSOPHENINE G/CN
E3	0 -->	ROSOVITINE/CN
E4	1	ROSOXACIN/CN
E5	1	ROSOXIDE/CN
E6	1	ROSPIGLIOSIDE/CN
E7	1	ROSPIGLIOSIDE AGLYCON/CN
E8	1	ROSPIN/CN
E9	1	ROSPINE/CN
E10	1	ROSPOL MP32/CN
E11	1	ROSS 160/CN
E12	1	ROSS WAX 160/CN

=> exp roscovitine/cn

E1	1	ROSCOPENIN/CN
----	---	---------------

```

E2          1      ROSCOVITIN/CN
E3          1 -->  ROSCOVITINE/CN
E4          1      ROSCOVITINE CARBOXYLIC ACID/CN
E5          1      ROSE ACETONE/CN
E6          1      ROSE ALLOY/CN
E7          1      ROSE B 1333/CN
E8          1      ROSE BD/CN
E9          1      ROSE BENGAL/CN
E10         1      ROSE BENGAL (131I) SODIUM/CN
E11         1      ROSE BENGAL 3-IODOPROPYL ESTER MONOSODIUM SALT/CN
E12         1      ROSE BENGAL 4-BROMOBUTYL ESTER MONOSODIUM SALT/CN

```

=> s e3

```
L10          1  ROSCOVITINE/CN
```

=> s purvalanol/cn

```
L11          0  PURVALANOL/CN
```

=> exp purvalanol/cn

```

E1          1      PURUSEA SQE 10C/CN
E2          1      PURUVATE DEHYDROGENASE COMPLEX, E2 COMPONENT, DIHYDROLIPOAMI
                DE ACETYLTRANSFERASE (LACTOBACILLUS SAKEI SAKEI STRAIN 23K G
                ENE PDHC)/CN
E3          0 -->  PURVALANOL/CN
E4          1      PURVALANOL A/CN
E5          1      PURVALANOL B/CN
E6          1      PUS/CN
E7          1      PUS (POLYMER)/CN
E8          1      PUS 1/CN
E9          1      PUS 2/CN
E10         1      PUS-A/CN
E11         1      PUS-B/CN
E12         1      PUS-C/CN

```

=> s e4-e5

```

                1  "PURVALANOL A"/CN
                1  "PURVALANOL B"/CN
L12          2  ("PURVALANOL A"/CN OR "PURVALANOL B"/CN)

```

=> exp olomoucine/cn

```

E1          1      OLOGEN/CN
E2          1      OLOMOUCIN/CN
E3          1 -->  OLOMOUCINE/CN
E4          1      OLOMOUCINE II/CN
E5          1      OLON/CN
E6          1      OLOPATADINE/CN
E7          1      OLOPATADINE HYDROCHLORIDE/CN
E8          1      OLOTHORB/CN
E9          1      OLPADRONATE/CN
E10         1      OLPADRONIC ACID/CN
E11         1      OLPI/CN
E12         1      OLPI/CN

```

=> s e3

```
L13          1  OLOMOUCINE/CN
```

=> file hcaplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

27.71

TOTAL

SESSION

72.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.10

FILE 'HCAPLUS' ENTERED AT 13:01:55 ON 02 MAY 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2009 VOL 150 ISS 19
 FILE LAST UPDATED: 1 May 2009 (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l10 or l12 or l13
      543 L10
      128 L12
      266 L13
L14      708 L10 OR L12 OR L13

=> s (l2 or l8) and l14
L15      3 (L2 OR L8) AND L14

=> d l15 1-3 ti abs bib
```

```
L15  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Compositions and methods using Stat3 pathway inhibitors or cancer stem
      cell inhibitors for combination cancer treatment
AB   The present invention relates to the composition and methods of use of Stat3
      pathway inhibitors or cancer stem cell inhibitors in combination treatment
      of cancer.
AN   2009:332545  HCAPLUS <<LOGINID::20090502>>
DN   150:345478
TI   Compositions and methods using Stat3 pathway inhibitors or cancer stem
      cell inhibitors for combination cancer treatment
IN   Li, Chiang Jia; Mikule, Keith; Li, Youzhi
PA   Boston Biomedical, Inc., USA
SO   PCT Int. Appl., 81pp.
      CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009036101	A1	20090319	WO 2008-US75906	20080910
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-971144P P 20070910
 US 2007-13372P P 20071213

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Antiproliferative effects of sapacitabine (CYC682), a novel
 2'-deoxycytidine-derivative, in human cancer cells
 AB This study assessed the antiproliferative activity of sapacitabine
 (CYC682, CS-682) in a panel of 10 human cancer cell lines with varying
 degrees of resistance or sensitivity to the commonly used nucleoside
 analogs ara-C and gemcitabine. Growth inhibition studies using
 sapacitabine and CNDAC were performed in the panel of cell lines and
 compared with both nucleoside analogs and other anticancer compds.
 including oxaliplatin, doxorubicin, docetaxel and seliciclib.
 Sapacitabine displayed antiproliferative activity across a range of
 concns. in a variety of cell lines, including those shown to be resistant
 to several anticancer drugs. Sapacitabine is biotransformed by plasma,
 gut and liver amidases into CNDAC and causes cell cycle arrest
 predominantly in the G2/M phase. No clear correlation was observed between
 sensitivity to sapacitabine and the expression of critical factors involved
 in resistance to nucleoside analogs such as deoxycytidine kinase (dCK),
 human equilibrative nucleoside transporter 1, cytosolic 5'-nucleotidase
 and DNA polymerase- α . However, sapacitabine showed cytotoxic
 activity against dCK-deficient L1210 cells indicating that in some cells,
 a dCK-independent mechanism of action may be involved. In addition,
 sapacitabine showed a synergistic effect when combined with gemcitabine
 and sequence-specific synergy with doxorubicin and oxaliplatin.
 Sapacitabine is therefore a good candidate for further evaluation in
 combination with currently used anticancer agents in tumor types with
 unmet needs.

AN 2007:959718 HCAPLUS <<LOGINID::20090502>>
 DN 148:92336

TI Antiproliferative effects of sapacitabine (CYC682), a novel
 2'-deoxycytidine-derivative, in human cancer cells
 AU Serova, M.; Galmarini, C. M.; Ghoul, A.; Benhadji, K.; Green, S. R.;
 Chiao, J.; Faivre, S.; Cvitkovic, E.; Le Tourneau, C.; Calvo, F.; Raymond,
 E.
 CS RayLab - Department of Medical Oncology, Hopital Beaujon, Clichy, 92110,
 Fr.
 SO British Journal of Cancer (2007), 97(5), 628-636
 CODEN: BJCAAI; ISSN: 0007-0920
 PB Nature Publishing Group
 DT Journal
 LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof
 AB A first aspect of the invention relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy- β -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy- β -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or sep. use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or sep. administering a CDK inhibitor and 1-(2-C-cyano-2-dioxy- β -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.
 AN 2005:523291 HCAPLUS <<LOGINID::20090502>>
 DN 143:48129
 TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof
 IN Green, Simon; Sleigh, Roger Neil
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005053699	A1	20050616	WO 2004-GB5081	20041203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1711185	A1	20061018	EP 2004-805910	20041203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007513132	T	20070524	JP 2006-542014	20041203
	US 20070270442	A1	20071122	US 2007-581585	20070420
PRAI	GB 2003-28180	A	20031204		
	WO 2004-GB5081	W	20041203		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT